Departments, Centers, & Programs:
Depression Clinical and Research Program
One Bowdoin Square
Boston, MA 02114-2790
- MD, New York University
- Residency, Massachusetts General Hospital
American Board Certifications
- Psychiatry, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Papakostas is involved in overseeing numerous studies focusing on the diagnosis, treatment, and management of Major Depressive Disorder that is resistant or refractory to standard therapy. He is also active in educating clinicians locally, regionally, nationally, and internationally on the management of major depressive disorder, as well as in disseminating cutting-edge research in this field of study through numerous manuscripts published in top-notch scientific journals. Dr. Papakostas is also co0author of the book entitled: "Parmacotherapy for Depression and Treatment-Resistant Depression" which, currently is the most up-to-date and comprehensive source document focusing on the treatment of this medical illness.
Papakostas GI, Fava M. Pharmacotherapy for Depression and Treatment-Resistant Depression. 1st Edition. Singapore: World Scientific Publishing; 2010.
Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors (SRIs) for SRI- non-responders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. (In press).
Nelson JC, Papakostas GI. Augmentation of Antidepressants with Atypical Antipsychotic Agents for Treatment-Resistant Depression: An updated meta-analysis. Am J Psychiatry. 2009; 166(9): 980-991.